$78.59
-1.35-1.69%
Last update: Oct 16, 6:11 PM
$78.54
-1.40-1.75%
Kiniksa Pharmaceuticals International PLC
KNSANASDAQ
Kiniksa Pharmaceuticals (KNSA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Kiniksa Pharmaceuticals (KNSA) last issued guidance on July 28, 2026 for fiscal year 2026. The company guided revenue in the range of $980M - $995M for the period.
Compared to prior guidance, Kiniksa Pharmaceuticals raised its revenue forecast from a prior range of $930M - $945M.
Kiniksa Pharmaceuticals has issued 7 guidance updates between February 25, 2025 and July 28, 2026. During this period, the company raised its outlook 6 times, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.30 | $0.16 | $0.35 | $0.35 |
| Actual | $0.30 | $0.27 | $0.17 | $0.23 |
| Surprise | 0.00% | +68.8% | -51.4% | -34.3% |
| Revenue | ||||
| Estimate | $226.7M | $205.6M | $200.9M | $166.8M |
| Actual | $243.6M | $214.3M | $202.1M | $180.9M |
| Surprise | +7.47% | +4.23% | +0.60% | +8.40% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.33 | $0.31 | $0.47 | $0.57 |
| Revenue | ||||
| Consensus | $260.0M | $276.5M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 28, 2026 | $0.30 | $0.30 | 0.00 % |
| Q1 | Apr 28, 2026 | $0.27 | $0.16 | 68.8 % |
| Q4 | Feb 24, 2026 | $0.17 | $0.35 | -51.4 % |
| Q3 | Oct 28, 2025 | $0.23 | $0.35 | -34.3 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 28, 2026 | $243.60M | $226.66M | 7.47 % |
| Q1 | Apr 28, 2026 | $214.30M | $205.59M | 4.23 % |
| Q4 | Feb 24, 2026 | $202.13M | $200.93M | 0.60 % |
| Q3 | Oct 28, 2025 | $180.86M | $166.84M | 8.40 % |
